Intermediate endpoints as surrogates for long term outcomes in breast cancer adjuvant chemotherapy trials

By afschroeder • August 22, 2025

Blasco A, López-Tarruella S, Urruticoechea A, Carrasco E, Spera G, Martín M, Bermejo B, Chap L, Ruiz-Borrego M, Crown J, García-Saenz JA, Chan A, Guerrero-Zotano Á, Semiglazov V, Calvo L, Pienkowski T, Herranz J, Slamon D. Intermediate endpoints as surrogates for long term outcomes in breast cancer adjuvant chemotherapy trials. Oncologist. 2025 Aug 21:oyaf263. doi: 10.1093/oncolo/oyaf263. Epub ahead of print. PMID: 40838872.

Tags: adjuvant chemotherapy, breast cancer, Early-stage, Hematology/Oncology, Publications, surrogate endpoint

Related Posts

Phase Ib/II trial of anti-CD33 monoclonal antibody BI 836858 and azacitidine in previously untreated older acute myeloid leukemia patients: Beat AML S2 sub-study results

Hochman MJ, Ruppert AS, Huang Y, Mims A, Borate U, Swords R, Traer E, Baer MR, Duong VH, Stock W, Odenike T, Patel P, Madanat[...]

Phase II randomised study of magrolimab combined with bevacizumab-FOLFIRI in patients with previously treated advanced inoperable metastatic colorectal cancer

Fakih M, Gill S, Sampat K, Chan DL, Fisher G, Cruz-Correa M, Lenz HJ, Garcia-Alfonso P, Forget F, Lonardi S, Krauss J, Chen E, Cubillo[...]

Clinical Outcomes of Lentiviral Vector Gene Therapy for Sickle Cell Disease

Prueksapraopong C, Fernandes A, Campo Fernandez B, Roy S, Hollis RP, Habtemariam B, Pellin D, Ceoldo G, Lin TY, Dang TT, Cornetta K, Romero Z,[...]